Benefits
Vascular dementia (Guekht 2011 PIVOTAL RCT)
Guekht 2011 (PMID 20656516, J Stroke Cerebrovasc Dis 20(4):310-318) large multicenter double-blind placebo-controlled trial in 242 patients with vascular dementia (VaD). 24 weeks treatment with cerebrolysin 20 mL IV daily for two 4-week courses + acetylsalicylic acid (ASA) vs ASA + placebo. RESULTS: Significant improvements in cognitive function (ADAS-cog+) and global clinical functioning (CIBIC+). Responder rates: ADAS-cog+ ≥4 points improvement 82.1% vs 52.2%; CIBIC+ <4 at week 24: 75.3% vs 37.4%; combined response 67.5% vs 27.0%. ODDS RATIO for favorable CIBIC+ response 5.08 (P<0.05); combined response OR 5.63 (P<0.05). Benefits PERSISTED ≥24 weeks. Among the strongest single RCT for any peptide nootropic.
Cochrane Review (Cui 2019) supports vascular dementia
Cui 2019 Cochrane review (PMID 23440834) — meta-analysis of 6 RCTs (n=597) with full data from 5 RCTs (Xiao 1999, Liang 2001, Zhang 2003, Muresanu 2008a, Guekht 2011). RESULTS: Cerebrolysin BENEFICIAL EFFECT on general cognitive function (MMSE WMD +1.10, 95% CI 0.37-1.82; ADAS-cog+ WMD -4.01, 95% CI -5.36 to -2.66). Improved global clinical function (RR 2.71, 95% CI 1.83-4.00). Only non-serious adverse events with no significant difference vs placebo. CONCLUSION: 'Cerebrolysin may improve cognitive and general function with few adverse effects in people with VaD' but 'substantial limitations in published studies' — not definitive evidence. Strongest racetam/peptide nootropic evidence base for vascular dementia.
Acute ischemic stroke recovery (CARS-1 + CARS-2 meta-analysis)
CARS-1 and CARS-2 trials (PMC5605586) — two identical-design prospective randomized double-blind placebo-controlled stroke studies. Cerebrolysin 30 mL daily IV for 3 weeks starting 24-72 h post-stroke. Meta-analysis showed significant improvements on NIHSS (National Institutes of Health Stroke Scale) at day 21 — Mann-Whitney 0.59, P=0.0010, NNT=7.1. BROADER 9-RCT meta-analysis (PMC5884916) confirmed early post-stroke neurological benefit with consistent methodology (30-50 mL within 72 h post-stroke for ≥1 week). Substantial evidence base for acute stroke neuroprotection.
Alzheimer's disease (multiple smaller RCTs)
Multiple AD trials (Bae 2000, Panisset 2002, Ruether 2001, Alvarez 2006, etc.) showed cerebrolysin benefits cognitive function, ADL, and global clinical impression in mild-moderate Alzheimer's disease. Effects more modest than vascular dementia. Used adjunct to acetylcholinesterase inhibitors in some Russian/European clinical practice.
Traumatic brain injury (CAPTAIN trials)
Cerebrolysin Acute Stroke and Traumatic Brain Injury (CAPTAIN) trials evaluated in moderate-severe TBI. Showed early neurological recovery improvements. Mechanism: neuroprotection during acute injury phase, neurotrophic support during recovery. Used in Russia and some European countries for TBI rehabilitation.
Multi-target neurotrophic mimicry
Cerebrolysin mimics endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF). Multi-target mechanism via active peptide fragments crossing BBB. Animal studies show: neuroprotection in cerebral ischemia, antiapoptotic effects, increased neurogenesis, reduced inflammation, enhanced neuroplasticity. Foundation for diverse clinical indications.
Mechanism of action
Endogenous neurotrophic factor mimicry
Active peptide fragments mimic endogenous BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial-derived neurotrophic factor), CNTF (ciliary neurotrophic factor). Provide trophic support to neurons that would otherwise be lost during ischemia, neurodegeneration, or aging. Multi-target mechanism distinguishes from single-receptor drugs.
Neuroprotection during ischemia/injury
Reduces excitotoxic damage, oxidative stress, and apoptosis during cerebral ischemia. Mechanism: peptide-mediated activation of cell survival pathways (PI3K/Akt, MAPK), reduced glutamate excitotoxicity, calcium homeostasis preservation. Foundation for stroke/TBI applications.
Enhanced neurogenesis and neuroplasticity
Stimulates neurogenesis in adult brain regions (hippocampus, subventricular zone). Supports synaptic plasticity and dendritic remodeling. Mechanism for cognitive recovery and improvement in chronic conditions. Active during rehabilitation phase post-stroke/TBI.
Anti-inflammatory effects
Reduces pro-inflammatory cytokine production in CNS. Mechanism for benefits in conditions with neuroinflammatory components — vascular dementia, post-stroke recovery, chronic neurodegeneration.
Antioxidant and metabolic support
Reduces oxidative stress markers. Improves cellular energy metabolism. Mechanism for cognitive enhancement claims and neuroprotection in metabolic stress states.
Cerebral blood flow and microcirculation effects
Some evidence for improved cerebral blood flow and microcirculation. Mechanism contributes to vascular dementia and stroke benefits. Less prominent than direct neurotrophic mechanisms.
Clinical trials
Multicenter randomized double-blind placebo-controlled trial (Guekht AB, Moessler H, Novak PH, Gusev EI 2011, J Stroke Cerebrovasc Dis 20(4):310-318, doi:10.1016/j.jstrokecerebrovasdis.2010.01.012, PMID 20656516). Sponsor: EVER Neuro Pharma.
242 patients meeting NINDS-AIREN criteria for vascular dementia. Cerebrolysin 20 mL IV daily for two 4-week treatment courses + acetylsalicylic acid vs placebo + ASA. Primary endpoint: combined cognition (ADAS-cog+) and global functioning (CIBIC+) at 24 weeks.
SIGNIFICANT IMPROVEMENT with cerebrolysin: ADAS-cog+ ≥4 points improvement 82.1% vs 52.2%; CIBIC+ <4 at week 24: 75.3% vs 37.4%; COMBINED RESPONSE 67.5% vs 27.0%. Odds ratio for favorable CIBIC+ response 5.08 (P<0.05); for combined response 5.63 (P<0.05). Benefits PERSISTED ≥24 weeks. SAFE AND WELL TOLERATED. Strongest single RCT for cerebrolysin in dementia. Limited by industry sponsorship.
Cochrane systematic review and meta-analysis (Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L 2019, Cochrane Database Syst Rev 11(11):CD008900, doi:10.1002/14651858.CD008900.pub3, PMID 23440834).
Six RCTs with total 597 participants with vascular dementia. Five RCTs provided full data for meta-analysis (Xiao 1999, Liang 2001, Zhang 2003, Muresanu 2008a, Guekht 2011).
Beneficial effect on general cognitive function: MMSE WMD +1.10 (95% CI 0.37-1.82); ADAS-cog+ WMD -4.01 (95% CI -5.36 to -2.66). Improved global clinical function: response rates RR 2.71 (95% CI 1.83-4.00). Only non-serious adverse events; no significant difference vs placebo (RR 0.97, 95% CI 0.49-1.94). Conclusion: 'Cerebrolysin MAY IMPROVE cognitive and general function with few adverse effects in people with VaD' but 'substantial limitations in published studies, and these data are NOT DEFINITIVE evidence of efficacy or safety.' Most rigorous independent meta-analysis.
Combined meta-analysis of CARS-1 and CARS-2 trials (Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D 2017, Neurol Sci 38(10):1741-1751, doi:10.1007/s10072-017-3037-z). PMC5605586.
Pooled patients from CARS-1 and CARS-2 — identical-design prospective randomized double-blind placebo-controlled trials. Cerebrolysin 30 mL daily IV for 3 weeks starting 24-72 h post-acute ischemic stroke + standardized 21-day rehabilitation program.
SIGNIFICANT EARLY NEUROLOGICAL BENEFIT: NIHSS Mann-Whitney 0.59 (P=0.0010), NNT=7.1 at day 21. Confirmed in broader 9-RCT meta-analysis (PMC5884916). Best methodological quality stroke evidence base for cerebrolysin. Industry-sponsored (EVER Neuro Pharma) but multi-center independent investigators.
About this ingredient
Cerebrolysin (FPF-1070, brand name Cerebrolysin, manufactured by EVER NEURO PHARMA GmbH, Austria) is a STANDARDIZED PEPTIDE PREPARATION derived from purified young porcine brain proteins by enzymatic breakdown. Composition: 15% PEPTIDES + 85% AMINO ACIDS. Active peptide fragments mimic endogenous neurotrophic factors — BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial-derived neurotrophic factor), CNTF (ciliary neurotrophic factor).
MULTI-TARGET MECHANISM: neurotrophic factor mimicry, neuroprotection during ischemia (reduces excitotoxicity, oxidative stress, apoptosis), enhanced neurogenesis and neuroplasticity, anti-inflammatory effects, antioxidant effects, cerebral microcirculation effects. ADMINISTRATION: PARENTERAL ONLY — IV (intravenous infusion) or IM (intramuscular injection); peptide preparation NOT bioavailable orally. Requires medical setting/professional administration.
REGULATORY STATUS: Approved in 50+ COUNTRIES including Russia, China, Germany, Austria, many European/Asian/CIS countries for: ACUTE ISCHEMIC STROKE (primary), VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, TRAUMATIC BRAIN INJURY, chronic cognitive disorders. NOT FDA-approved in US — limited US availability through compounding/research channels. CLINICAL EVIDENCE BASE (most robust among 'Russian peptide' nootropics): GUEKHT 2011 PMID 20656516 PIVOTAL VaD RCT (n=242, 24 weeks, large effect sizes); CUI 2019 COCHRANE REVIEW PMID 23440834 (6 RCTs n=597, beneficial cognitive and global function effects); CARS-1 + CARS-2 STROKE TRIALS with significant early neurological benefit; 9-RCT broader meta-analysis (PMC5884916) confirming early post-stroke benefit; multiple AD trials (Bae 2000, Panisset 2002, Alvarez 2006); CAPTAIN TBI trials.
EVIDENCE: 3/5 reflects: (1) Guekht 2011 PIVOTAL VaD RCT with substantial effect sizes, (2) Cui 2019 Cochrane review with positive meta-analysis but 'not definitive' caveat, (3) CARS-1/CARS-2 meta-analysis demonstrating stroke benefit, (4) extensive AD clinical evidence base, (5) approval in 50+ countries, (6) multi-target neurotrophic factor mechanism, (7) industry sponsorship of pivotal trials (EVER Neuro Pharma) — important conflict caveat, (8) parenteral-only administration limits practical accessibility. SAFETY: Excellent — only non-serious adverse events in meta-analysis; 30+ years European/Asian clinical experience supports safety profile. Best positioned as: (a) VASCULAR DEMENTIA adjunct in countries where approved, with strongest single-RCT evidence, (b) ACUTE ISCHEMIC STROKE adjunct (CARS-1/CARS-2 evidence) for those treated 24-72h post-stroke under medical care, (c) ALZHEIMER'S adjunct (more modest evidence, used with cholinesterase inhibitors), (d) TBI rehabilitation adjunct, (e) NOT FDA-approved — practical accessibility limitations in US (research/compounding channels only), (f) PARENTERAL-ONLY administration limits use to medical settings, (g) significant cost compared to oral nootropics.
Honest framing: cerebrolysin has the STRONGEST evidence base among peptide nootropics — pivotal Guekht 2011 RCT in vascular dementia with substantial effect sizes, Cochrane meta-analysis showing benefit, CARS stroke trials with consistent results, and approval in 50+ countries. Industry-sponsored pivotal trial warrants caveat. Multi-target neurotrophic factor mimicry mechanism is biochemically robust.
PRACTICAL LIMITATIONS: parenteral-only administration, significant cost, US regulatory unavailability. For those with access in approved countries, reasonable evidence-based intervention for stroke recovery and vascular dementia under medical supervision.